04 Apr
Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass. , April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s
10 Mar
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune
03 Mar
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Provide Business Update
WATERTOWN, Mass. , March 03, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated, precision immune tolerance platform, ImmTOR ® , to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today
09 Feb
Selecta Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
WATERTOWN, Mass. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
10 Jan
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicity WATERTOWN, Mass. and BOSTON , Jan.
05 Jan
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
WATERTOWN, Mass. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management